Fixed-dose combinations in type 2 diabetes – role of the canagliflozin metformin combination

Canagliflozin–metformin is one of the newest combination therapies available for the treatment of type 2 diabetes mellitus (T2DM). Canagliflozin is an inhibitor of the sodium–glucose co-transporter 2 which causes an increase in the urinary excretion of glucose. In the present article, we review the...

Descripción completa

Detalles Bibliográficos
Autores principales: Fleming, Joshua W, Fleming, Laurie W, Davis, Courtney S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4485795/
https://www.ncbi.nlm.nih.gov/pubmed/26150733
http://dx.doi.org/10.2147/DMSO.S69282

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4485795/
https://www.ncbi.nlm.nih.gov/pubmed/26150733
http://dx.doi.org/10.2147/DMSO.S69282

Ejemplares similares